Siddhartha Mukherjee is something of a biotech Renaissance man. First and foremost, he sees himself as an oncologist. But ...

If you want to get a pulse on digital health, Missy Krasner is an excellent person to ask. For the last several years, ...

Nabla Bio, a small startup founded by scientists from geneticist George Church’s lab at Harvard Medical School, has formed ...

In a new analysis of Novo Nordisk’s vast SELECT study, researchers may have a better answer for one of the biggest questions ...

More details have started to emerge on how exactly Bayer is executing its broader company restructuring. The German ...

Pfizer may be the next pharma giant to launch a direct-to-consumer platform. The company applied in April to trademark ...

A large number of patient dropouts caused by immune side effects have forced Merck to end a late-stage trial of its ...

Member countries of the World Health Organization said they failed to agree on a draft of a long-awaited pandemic agreement ...

Cardurion Pharmaceuticals touted positive data for its heart failure drug and announced plans to pursue two more trials, ...

The battle between pharma companies and hospitals over the federal drug discount program known as 340B is gaining steam as its size has tripled since 2018 and may even double again, according to a new ...

Cytokinetics detailed results on Monday from a late-stage trial of aficamten for a rare heart disease, and the company is ...

Sanofi will pay $80 million upfront to snag the ex-US license to Fulcrum Therapeutics' rare neuromuscular disease treatment ...